Cytogenetic and molecular analysis in Philadelphia negative CML

Cytogenetic and molecular analysis in Philadelphia negative CML.

We studied the clinical, hematologic, cytogenetic and molecular biologic features in four patients with Philadelphia (Ph) negative chronic myeloid leukemia (CML). In all four cases the clinical and hematologic characteristics were indistinguishable from Ph positive CML. Cytogenetic analysis showed a normal karyotype in two patients and chromosomal translocations apparently not affecting chromos...

Philadelphia-Negative (Ph-) Chronic Myeloid Leukemia (CML): Comparison With Ph' CML and Chronic Myelomonocytic Leukemia

To better understand the Philadelphia-negative (Ph-) chronic myeloid leukemia (CML) and its relationships with Philadelphia-positive (Ph') CML and chronic myelomonocytic leukemia (CMML), a study was undertaken by the Groupe Franpais de Cytogenetique Hematologique. Thirty-five PhCML patients were investigated and compared with 55 chronic phase Ph+ CML and 100 CMML patients. There were 12 M-BCR p...

A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML

Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome, an acquired clonal abnormality resulting from translocation of chromosomes 9 and 22, and the generation of the BCR–ABL fusion oncogene. The development of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of CML, as TKI therapy leads to inhibition of BCR–ABL activity, suppression of the BCR–ABL-...

Molecular Mechanisms in Philadelphia Negative Myeloproliferative Neoplasia

Diagnosis and Disease Management in CML Patients Using Conventional and Molecular Cytogenetics

Chronic Myeloid Leukemia (CML) is a hematopoietic malignancy characterized by the presence ofPhiladelphia (Ph1) chromosome that results from balanced reciprocal translocation between chromosomes9 and 22 leading in the formation of bcr/abl fusion gene. The present study was conducted to evaluate cytogenetic and molecular abnormalities in CML patients at presentation and during the co...